Table 6.

Active combinatorial trials in gastrointestinal cancers.

Trial ID	Cancer	PARP inhibitor	Immunotherapy	Phase
NCT02484404	Colorectal	Olaparib	Atezolizumab (PD-L1) cediranib (VEGFR)	I/II
NCT02660034	•HER2-negative gastric •Gastroesophageal junction •Advanced pancreatic	BGB-290	BGB-A317 (PD-1)	I/II
NCT03851614	•Advanced pancreatic •dMMR colorectal	Olaparib	Durvalumab (PD-1)	I/II
NCT03404960	Advanced pancreatic	Niraparib	Nivolumab (PD-1) ipilimumab (CTLA-4)	I/II
NCT03637491	Advanced pancreatic	Talazoparib	Avelumab (PD-1)	I/II
NCT02734004	Relapsed gastric	Olaparib	Durvalumab (PD-L1) +/− bevacizumab	I/II
NCT03639935	Biliary	Rucaparib	Nivolumab (PD-1)	II